Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The company delivers news and insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Zynex, Inc. has announced a partnership with Veterans Affairs Medical Centers (VAMCs) to enhance access to noninvasive pain management solutions for veterans [1][4] - The VA spends over $112 billion annually on healthcare, servicing over 9 million enrolled veterans, presenting a significant market opportunity for Zynex [2][3] - Currently, less than 1% of Zynex's sales come from VAMCs, indicating substantial potential for sales expansion within the largest healthcare network in the U.S. [2][4] Company Overview - Zynex, founded in 1996, specializes in the development, manufacturing, marketing, and sale of medical devices for pain management and rehabilitation [5] - The company also produces non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospital use [5] Market Context - The Department of Veterans Affairs operates 171 VAMCs and over 1,100 outpatient facilities, alongside approximately 700 Military Treatment Facilities (MTFs) managed by the Department of Defense, creating a vast healthcare network for veterans and service members [3]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of Californi ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University.Trial completion is a key milestone required by the FDA ...

ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.The Open Oximetry Project, an initiative led by the University of California, San Francisco' ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Company Performance - Zynex Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.10 per share a year ago, representing a 40% earnings surprise [1] - The company posted revenues of $49.97 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.86%, and showing a slight increase from $49.92 million year-over-year [1] - Over the last four quarters, Zynex has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [1] Stock Outlook - Zynex shares have declined approximately 23.2% since the beginning of the year, contrasting with the S&P 500's gain of 21.5% [2] - The company's earnings outlook is uncertain, with unfavorable estimate revisions leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] - Current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $53.85 million, and for the current fiscal year, it is $0.20 on revenues of $200.66 million [4] Industry Context - The Medical - Products industry, to which Zynex belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Another company in the same industry, Curaleaf Holdings, Inc., is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +33.3%, with revenues projected at $348.52 million, up 4.6% from the previous year [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) Common Stock, par value $0.001 p ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...